PTLD treatment: reducing the chemotherapy burden through addition of rituximab.
Dharnidharka
Vikas R
VR
Gupta
Sushil
S
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D006084:Graft Rejection / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D016377:Organ Transplantation / Q000009:adverse effects*; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab